Get the Weekly Intelligence Brief — top committee picks every Sunday.

GMED vs TEVA

Globus Medical vs Teva Pharmaceutical Industries Limited — AI-powered side-by-side comparison
GMED
Globus Medical
71
Buy
VS
TEVA
Teva Pharmaceutical Industries Limited
55
Watch
MetricGMEDTEVA
AI Score 71 55
Price $85.12 $36.49
P/E Ratio 21.45× 57.19×
ROE 11.8% 17.8%
Revenue Growth YoY
Gross Margin 68.5% 52.5%
Debt / Equity 0.02× 2.16×
Dividend Yield 0.0% 0.0%
RSI (14) 75.9 77.8
Beta 0.954 0.864
Expected Upside +0.1%

AI Committee View

Current Innellis committee reasoning for GMED versus TEVA.
GMED leads by 16 points.

GMED scores 71/100 (Buy) versus TEVA at 55/100 (Watch).

GMED Committee View
75% agreement
4 analysts

The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is rsi at 76 is in overbought territory. The committee is constructive but not yet at full conviction.

Bull Case
  • 5 consecutive earnings beats -- consistent execution — Growth
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
  • MACD histogram positive -- bullish momentum — Technical
Bear Case
  • RSI at 76 is in overbought territory — Technical
  • Price trading above the upper Bollinger Band -- stretched — Technical
TEVA Committee View
50% agreement
6 analysts

The committee is genuinely divided. News Analyst sees a compelling case — news sentiment is positive (+0.63 across 21 articles, 14d). Value Analyst remains cautious — p/e of 57.5 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.

Bull Case
  • Price structure making higher highs and higher lows — Technical
  • MACD histogram positive -- bullish momentum — Technical
  • Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
  • P/E of 57.5 is expensive by classic value standards — Value
  • Price-to-book of 4.9x prices in significant intangible value — Value
  • Debt-to-equity of 2.12 adds balance-sheet risk to the value case — Value
Want the full breakdown?
Committee votes, technicals, and trade plans for both companies.
GMED Full Analysis TEVA Full Analysis